Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes

Journal of Hypertension

Volumn 27, Issue 12, 2009, Pages 2365-2376

  Larrayoz, Ignacio M ^a   Pang, Tao ^a   Benicky, Julius ^a   Pavel, Jaroslav ^a   Sśnchez Lemus, Enrique ^a   Saavedra, Juan M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Angiotensin receptor blockers; Cytokines; Inflammation; Inhibitor of kappa B alpha; Interleukin 6; Interleukin 1 beta; Reninangiotensin system; Transcription factors; Tumor necrosis factor alpha

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BACTERIUM LIPOPOLYSACCHARIDE; CANDESARTAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INNATE IMMUNITY; MONOCYTE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 73649092442     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283314bc7     Document Type: Article

References (61)

1. Pastore L, Tessitore A, Martinotti S, Toniato E, Alesse E, Bravi MC, ef al. Angiotensin II stimulates intercellular adhesion moleoule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100: 1646-1652. (Pubitemid 29477275)
2. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vase Biol 2000; 20: 645-651. (Pubitemid 30151676)
3. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11: RA194-RA205.
4. Savoia C, Schiffrin EL. Inhibition of the renin angiotensin system: implications for the endothelium. Curr Diab Rep 2006; 6: 274-278. (Pubitemid 44322699)
5. Dzau VJ. Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001 ; 37: 10471052.
6. Nickenig G. Central role of the AT(1)-receptor in atherosclerosis. J Hum Hypertens 2002; 16: S26-S33.
7. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35: 881 900.
8. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003; 88: 4496-4501. (Pubitemid 37153762)
9. Ando H, Zhou J, Macova M, lmboden H, Saavedra JM. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004; 35: 1726-1731. (Pubitemid 38823655)
10. Zhou J, Ando H, Macova M, Dou J, Saavedra JM. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab 2005; 26: 878-886. (Pubitemid 40905615)
11. Ghladoni L, Virdis A, Magagna A, Taddei S, Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35: 501-506. (Pubitemid 30054224)
12. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000; 35:714-721. (Pubitemid 30167029)
13. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 2003; 26: 691-697. (Pubitemid 37258655)
14. Koh KK, Quon MJ, Han SH, Chung WJ, Lee Y, Shin EK. Anti-inflammatory and metabolic effects of candesartan In hypertensive patients. Int J Cardiol 2006; 108: 96-100. (Pubitemid 43324913)
15. Salzet M, Deloffre L, Breton C, Vieau D, Schoofs L. The angiotensin system elements in invertebrates. Brain Res Brain Res Rev 2001 ; 36: 35-45.
16. Jerala R. Structural biology of the LPS recognition. Int J Med Microbiol 2007; 297: 353-363.
17. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376.
18. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001; 13: 85-94. (Pubitemid 32222977)
19. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.
20. Hashimoto S-J, Morohoshi K, Suzuki T, Matsushima K. Lipopolysaccharideinducible gene expression profile in human monocytes. Scand J Infect Dis 2003; 36: 619-627. (Pubitemid 37336883)
21. Hawiger J. Innate immunity and inflammation: a transcriptional paradigm. Immunol Res 2001 ; 23: 99-109. (Pubitemid 32575352)
22. Kim MP, Zhou M, Wahl LM. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol 2005; 78: 195-201.
23. Egidy G, Friedman J, Viswanathan M, Wahl LM, Saavedra JM. CGP-42112 partially activates human monocytes and reduces their stimulation by lipopolysacoharldes. Am J Physiol 1997; 273: C826-C833.
24. Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 1991; 261: R209-R216.
25. Yamakawa H, Jezova M, Ando H, Saavedra JM. Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition. J Cereb Blood Flow Metab 2003; 23: 371-380. (Pubitemid 36307581)
26. Yang CS, Lee HM, Lee JY, Kim JA, Lee SJ, Shin DM, et al. Reactive oxygen species and p47phox activation are essential for the Mycobacterium tuberculosis-induced proinflammatory response in murine microglia. J Neuroinflammation 2007; 4: 27-45.
27. Suzuki T, Hashimoto S, Toyoda N, Nagai S, Yamazaki N, Dong HY, et al. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Stood 2000; 96: 2584-2591. (Pubitemid 30745285)
28. Velasco M, Diaz-Guerra MJ, Martin-Sanz P, Alvarez A, Bosca L. Rapid upregulation of IkappaBbeta and abrogation of NF-kappaB activity in peritoneal macrophages stimulated with lipopolysaccharide. J Biol Chem 1997; 272: 23025-23030. (Pubitemid 27392426)
29. Zhang FX, Kirschning CJ, Mancinelli R, Xu XP, Jin Y, Faure E, et al. Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem 1999; 274: 7611-7614. (Pubitemid 129518142)
30. Park HS, Jung HY, Park EY, Kim J, Lee WJ, Bae YS. Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B. J Immunol 2004; 173: 3589-3593. (Pubitemid 39280716)
31. Lu Y, Wahl LM. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-kappa B activity in lipopolysaccharide-activated human primary monocytes. J Immunol 2005; 175: 5423-5429. (Pubitemid 41456428)
32. Draude G, Hrboticky N, Lorenz RL. The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem Pharmacol 1999; 57: 383-386. (Pubitemid 29065286)
33. Morawietz H. LOX-1 and atherosclerosis: proof of concept in LOX-1 knockout mice. Circ Res 2007; 100: 1534-1536. (Pubitemid 46897254)
34. Nagase M, Abe J, Takahashi K, Ando J, Hirose S, Fujita T. Genomic organization and regulation of expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) gene. J Biol Chem 1998; 273: 33702-33707. (Pubitemid 29005759)
35. Jiang Q, Akashi S, Miyake K, Petty HR. Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. J Immunol 2000; 165: 3541-3544. (Pubitemid 32057253)
36. Singh AK, Jiang Y. How does peripheral lipopolysaccharide induce gene expression in the brain of rats? Toxicology 2004; 201: 197-207. (Pubitemid 39023946)
37. Vakharia K, Hinson JP. Lipopolysaccharide directly stimulates Cortisol secretion by human adrenal cells by a cyclooxygenase-dependent mechanism. Endocrinology 2005; 146: 1398-1402. (Pubitemid 40289328)
38. Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal l. High glucose induces toll-like receptor expression in human monocytes. Mechanism of activation. Diabetes 2008; 57: 3090-3098.
39. Froy O, Hananel A, Chapnik N, Madar Z. Differential effect of insulin treatment on decreased levels of beta-defensins and Toll-like receptors in diabetic rats. Mol Immunol 2007; 44: 796-802. (Pubitemid 44415013)
40. Zhang H, Sun GY. LPS induces permeability injury in lung microvascular endothelium via AT(1 ) receptor. Arch Biochem Biophys 2005; 441: 75-83. (Pubitemid 41188354)
41. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, et al. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999; 17: 537-545. (Pubitemid 29308564)
42. Mlura R, Nakamura K, Miura D, Miura A, Hisamatsu K, Kajlya M, et al. Aldosterone synthesis and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Sci 2006; 102: 288-295. (Pubitemid 44790690)
43. Dörfell Y, Latsch C, Stuhlmüller B, Schreiber S, Scholze S, Bermester GR, Scholze J. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34: 113-117. (Pubitemid 29325728)
44. Simon MR, Kamlay MT, Khan M, Melmon K. Angiotensin II binding to human mononuclear cells. Immunopharmacol Immunotoxicol 1989; 11: 63-80. (Pubitemid 19173530)
45. Weinberg AJ, Zappe DH, Ashton M, Weinberg MS. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol 2004; 24: 340-345.
46. Lee JW, Naidong W, Johnson T, Dzerk A, Miyabayashi T, Motohashi M. Development and validation of column-switching high-performance liquid chromatographic methods for the determination of a potent All receptor antagonist, TCV-116, and its metabolites in human serum and urine. J Chromatogr B Biomed Appl 1995; 670: 287-298.
47. Seeger H, Lippert C, Wallwiener D, Mueck AO. Valsartan and candesartan can inhibit deteriorating effects of angiotensin II on coronary endothelial function. J Renin Ang Aldost System 2001 ; 2: 141-143.
48. Yanagitani Y, Rakugi H, Okamura A, Moriguchi K, Takiuchi S, Ohishi M, et al. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 1999; 33 (part II): 335-339. (Pubitemid 29065681)
49. Gloire G, Legrand-Poels S, Piette J. NF-KB activation by reactive oxygen species: fifteen years later. Biochem Pharm 2006; 72: 1493-1505. (Pubitemid 44666727)
50. Nishi K, Oda T, Takabuohi S, Oda S, Fukuda K, Adachi T, et al. LPS induces hypoxia-inducible factor 1 activation in macrophage-differentiated cells in a reactive oxygen species-dependent manner. Antioxid Redox Signal 2008; 10: 983-995. (Pubitemid 351301367)
51. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253-2261. (Pubitemid 39625096)
52. Watanabe T, Suzuki J, Yamawaki H, Sharma VK, Sheu SS, Berk BC. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179. Circulation 2005; 112: 1798-1805. (Pubitemid 41368156)
53. Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model 2006; 3:1-33.
54. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, et al. Molecular activation of PPARgamma by angiotensin II type 1 -receptor antagonists. Vascul Pharmacol 2006; 45: 154-162. (Pubitemid 44716729)
55. Nagai N, Oike Y, Izumi-Nagai K, Urano T, Kubota Y, Noda K, et al. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol 2006; 26: 2252-2259. (Pubitemid 44465719)
56. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, Saavedra JM. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006; 552: 112-122. (Pubitemid 44754970)
57. Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, Friedl Jl, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 2006; 36: 361-370. (Pubitemid 43257459)
58. Chen S, Ge Y, Si J, Rifai A, Dworkin LD, Gong R. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int 2008; 74: 1128-1138.
59. Grove KL, Speth RC. Angiotensin II and nonangiotensin II displaceable binding sites for [3H]losartan in the rat liver. Biochem Pharmacol 1993; 46: 1653-1660.
60. Chansel D, Vandermeersch S, Pham P, Ardaillou R. Characterization of [3H]losartan in isolated rat glomeruli. Eur J Pharmacol 1993; 247: 193198.
61. Grothusen C, Umbreen S, Konrad I, Stellos K, Schulz C, Schmidt B, et al. EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1 -receptor antagonism. Arterioscler Thromb Vasc Biol 2007; 27: 1184-1190. (Pubitemid 46641977)